Arovella Lands CAR-T Pioneer to Guide ALA-101 to First Human Trial in Q3 2026
Arovella Therapeutics has appointed Professor Cameron Turtle to its Clinical Advisory Board and Dr Sam Fiorenza as Lead Principal Investigator for the company’s first-in-human trial of ALA-101, scheduled to commence in Q3 2026 at The Alfred in Melbourne. ALA-101 is an allogeneic CD19 CAR iNKT-cell therapy targeting blood cancers and autoimmune diseases.
The dual appointments come at a strategically important time, directly supporting operational readiness for the company’s most significant near-term clinical milestone. The trial remains on track for its planned start date later this year.
Professor Turtle brings proven CAR-T development track record
Professor Turtle is an internationally recognised leader in cellular immunotherapy with extensive experience in novel cell therapies. His credentials include:
- Professor and CLEARbridge Chair in Cancer Immunotherapy at the University of Sydney
- Medical Director of the Immune Effector Cell Service at Royal North Shore Hospital
- 17 years at Fred Hutchinson Cancer Center in Seattle, where he held the role of Professor and Anderson Family Endowed Chair for Immunotherapy
During his tenure at Fred Hutchinson, Professor Turtle led clinical and laboratory research programmes in CAR T-cell therapy for blood cancers. His work on early clinical studies of CD19 CAR T-cell therapies helped inform the development of Breyanzi (lisocabtagene maraleucel), a now-approved CD19 CAR T-cell therapy for several B-cell malignancies.
The appointment adds credibility to Arovella’s clinical strategy and provides access to global clinical, academic and pharmaceutical networks. Professor Turtle’s direct involvement in therapies that achieved regulatory approval and commercialisation demonstrates relevant experience for guiding ALA-101 through its clinical pathway.
When big ASX news breaks, our subscribers know first
What are CAR iNKT cells and why do they matter?
iNKT cells, or invariant Natural Killer T cells, are a specialised type of immune cell that can be engineered to target cancer. Arovella’s ALA-101 therapy modifies these cells with a Chimeric Antigen Receptor (CAR) that targets CD19, an antigen found on the surface of numerous cancer types.
A key advantage of ALA-101 is its allogeneic or “off-the-shelf” manufacturing approach. Unlike autologous CAR-T therapies that require each patient’s own cells to be harvested and modified, ALA-101 can be manufactured from healthy donors and administered to multiple patients. This potentially lowers manufacturing costs and increases scalability compared to patient-specific products.
ALA-101 also features dual targeting capability. The therapy targets CD19 via its CAR and can simultaneously target CD1d-expressing tumours via its invariant T-cell receptor. This dual mechanism may address limitations in current T-cell therapies.
Professor Cameron Turtle
“I am delighted to join Arovella’s Clinical Advisory Board at this stage in the clinical development of ALA-101 for haematological cancers. Despite the major advances achieved with T-cell therapies, important challenges remain, including timely patient access, manufacturing complexity, durability of response and tumour escape. ALA-101 has been designed with several important differentiating features, including its off-the-shelf allogeneic CAR-iNKT platform and its potential for dual tumour antigen targeting. I look forward to working with the Arovella team as they advance this promising program into clinical evaluation for patients with CD19-positive blood cancers.”
Dr Fiorenza takes Lead Principal Investigator role
Dr Sam Fiorenza has been appointed as Lead Principal Investigator for the first-in-human clinical trial at The Alfred. His transition to this role is based on his deep understanding of the ALA-101 programme and ensures strong clinical leadership for the trial.
Acting CEO Dr Nicole van der Weerden commented on the appointments: “Professor Turtle’s extensive experience in developing and delivering transformative cell therapies will be invaluable as we advance ALA-101 in the clinic. We also thank Dr Fiorenza for accepting the pivotal role of Lead Principal Investigator for our first clinical study.”
ALA-101 programme snapshot
ALA-101 has achieved US FDA IND acceptance and is being developed for dual indications: blood cancers and autoimmune diseases. The company is also expanding its pipeline into solid tumour treatment through CLDN18.2-targeting technology licenced from Sparx Group and IL-12-TM technology.
CLDN18.2-targeting pipeline expansion has added a solid tumour dimension to Arovella’s programme, with preclinical data showing tumour kill rates exceeding 97% in pancreatic cancer cell lines and IL-12-TM armouring sustaining cell activity across four serial challenge rounds.
FDA IND acceptance for ALA-101 cleared the regulatory pathway for Phase 1 trials across both US and Australian sites, a critical de-risking step that validated the allogeneic CAR-iNKT platform ahead of first patient dosing.
| Programme | Target | Indication | Regulatory Status | Next Milestone |
|---|---|---|---|---|
| ALA-101 | CD19 / CD1d | Blood cancers, autoimmune diseases | US FDA IND accepted | First-in-human trial Q3 CY26 |
The technology platform is licenced from Imperial College London and represents Arovella’s lead programme in cell therapy development.
The next major ASX story will hit our subscribers first
What comes next for Arovella investors
The Q3 2026 trial commencement represents the key near-term catalyst for the company. Successful initiation would validate operational execution and open the pathway to clinical data catalysts from safety and efficacy readouts.
Chairman David Williams emphasised the urgency driving the programme forward.
Chairman David Williams
“Patients are desperate for a solution, including participating in what might be a breakthrough clinical trial and treatment. We owe it to those patients, their clinicians, and ourselves, to get into the clinic as soon as possible.”
The clinical leadership appointments position Arovella to execute on this timeline, with both Professor Turtle’s external expertise and Dr Fiorenza’s internal programme knowledge supporting trial readiness. Investors will watch for trial initiation news in Q3 2026, followed by early-stage data readouts as the study progresses.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving clinical trial updates and FDA decisions break.